Advanced Melanoma
98
24
34
29
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
23 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
10.2%
10 terminated out of 98 trials
74.4%
-12.1% vs benchmark
8%
8 trials in Phase 3/4
79%
23 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (98)
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Sitagliptin With Pembro in RCC and Melanoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
A Phase II Trial of LM103 in Advanced Melanoma
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer